Literature DB >> 32473876

Seroprevalence of chronic hepatitis B virus infection and immunity to measles, rubella, tetanus and diphtheria among schoolchildren aged 6-7 years old in the Solomon Islands, 2016.

Lucy Breakwell1, Jenniffer Anga2, Gretchen Cooley3, Laura Ropiti2, Sarah Gwyn3, Kathleen Wannemuehler4, Joseph Woodring5, Divinal Ogaoga2, Diana Martin3, Minal Patel4, Rania A Tohme4.   

Abstract

The Western Pacific Region (WPR) established a goal to decrease chronic hepatitis B virus (HBV) infection among children to <1% and to achieve ≥95% hepatitis B vaccine birth dose (HepB-BD) and ≥95% three-dose (HepB3) coverage by 2017. In 2016, we conducted a national serosurvey in the Solomon Islands among 6-7-year-old school children to assess progress towards the control goal and immunity to measles, rubella, tetanus and diphtheria. Eighty schools were selected systematically proportional to their 6-7-year-old population; all 6-7-year-olds were enrolled. We collected basic demographic information and vaccination history. Children were tested for HBV surface antigen (HBsAg) using a rapid test, and for immunity to measles, rubella, tetanus, and diphtheria using a multiplex bead assay. In total, 1,249 out of 1,492 children (84%) were enrolled, among whom 1,169 (94%) underwent HBsAg testing and 1,156 (93%) provided dried blood spots. Almost 80% (n = 982) of enrolled children had vaccination cards, among whom 59% (n = 584) received a timely HepB-BD (within 24 hours of birth), 95% (n = 932) received HepB3, and >90% received vaccines for diphtheria, tetanus, and measles (rubella vaccine was not available at the time). HBsAg prevalence was 3.1% (95% confidence interval (CI): 2.0%-4.9%), with 55% of identified cases from one province. Among 982 children with vaccination cards, HBsAg prevalence was higher among children who had not received a timely HepB-BD and at least two HepB doses compared to those who had (4% vs. 2%). Of 1,156 tested children, immunoprotection estimates were 99% (95% CI: 98%-99%) for measles, 99% (95% CI: 97%-100%) for rubella, 85% (95% CI: 83%-87%) for tetanus, and 51% (95% CI: 47%-55%) for diphtheria. Improving timely HepB-BD coverage and maintaining high HepB3 coverage could help Solomon Islands reach the regional HBV control goal. Low immunity to tetanus and diphtheria suggests the need to introduce booster doses to ensure long-term protection. Published by Elsevier Ltd.

Entities:  

Keywords:  Hepatitis B; Hepatitis B surface antigen; Immunity; Immunization; Seroepidemiological studies; Solomon Islands; Vaccination; Vaccine preventable diseases

Mesh:

Substances:

Year:  2020        PMID: 32473876      PMCID: PMC7530912          DOI: 10.1016/j.vaccine.2020.05.029

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  Chronic hepatitis B.

Authors:  A S Lok; B J McMahon
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

Review 2.  Rubella immunity. Defining the level of protective antibody.

Authors:  L P Skendzel
Journal:  Am J Clin Pathol       Date:  1996-08       Impact factor: 2.493

3.  Evaluation of storing hepatitis B vaccine outside the cold chain in the Solomon Islands: Identifying opportunities and barriers to implementation.

Authors:  Lucy Breakwell; Jenniffer Anga; Ibrahim Dadari; Nahad Sadr-Azodi; Divinal Ogaoga; Minal Patel
Journal:  Vaccine       Date:  2017-04-18       Impact factor: 3.641

4.  Comparison of a multiplex flow cytometric assay with enzyme-linked immunosorbent assay for auantitation of antibodies to tetanus, diphtheria, and Haemophilus influenzae Type b.

Authors:  Jerry W Pickering; Thomas B Martins; M Carl Schroder; Harry R Hill
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

5.  Baculovirus expression of the nucleoprotein gene of measles virus and utility of the recombinant protein in diagnostic enzyme immunoassays.

Authors:  K B Hummel; D D Erdman; J Heath; W J Bellini
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

6.  Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccine.

Authors:  Lei Zhang; Xi-en Gui; Caroline Teter; Hairong Zhong; Zhiyong Pang; Lixiong Ding; Fengliang Li; Yun Zhou; Ling Zhang
Journal:  Vaccine       Date:  2014-09-18       Impact factor: 3.641

7.  Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France.

Authors:  Julie Bottero; Anders Boyd; Joel Gozlan; Maud Lemoine; Fabrice Carrat; Anne Collignon; Nicolas Boo; Philippe Dhotte; Brigitte Varsat; Gérard Muller; Olivier Cha; Odile Picard; Jean Nau; Pauline Campa; Benjamin Silbermann; Marc Bary; Pierre-Marie Girard; Karine Lacombe
Journal:  J Hepatol       Date:  2012-11-23       Impact factor: 25.083

8.  Multiplex Serologic Assessment of Schistosomiasis in Western Kenya: Antibody Responses in Preschool Aged Children as a Measure of Reduced Transmission.

Authors:  Kimberly Y Won; Henry M Kanyi; Faith M Mwende; Ryan E Wiegand; E Brook Goodhew; Jeffrey W Priest; Yeuk-Mui Lee; Sammy M Njenga; W Evan Secor; Patrick J Lammie; Maurice R Odiere
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

9.  Integrated Cross-Sectional Multiplex Serosurveillance of IgG Antibody Responses to Parasitic Diseases and Vaccines in Coastal Kenya.

Authors:  Sammy M Njenga; Henry M Kanyi; Benjamin F Arnold; Sultani H Matendechero; Joyce K Onsongo; Kimberly Y Won; Jeffrey W Priest
Journal:  Am J Trop Med Hyg       Date:  2020-01       Impact factor: 2.345

10.  Impact of Mothers' Schistosomiasis Status During Gestation on Children's IgG Antibody Responses to Routine Vaccines 2 Years Later and Anti-Schistosome and Anti-Malarial Responses by Neonates in Western Kenya.

Authors:  Bartholomew N Ondigo; Erick M O Muok; John K Oguso; Sammy M Njenga; Henry M Kanyi; Eric M Ndombi; Jeffrey W Priest; Nupur Kittur; William Evan Secor; Diana M S Karanja; Daniel G Colley
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.